CombiMatrix Presents Preliminary Data on Comprehensive Cancer Array Test | GenomeWeb

An investigational microarray test that measures miRNA expression patterns to detect the presence of cancer and distinguish between cancers has yielded promising preliminary data, according to CombiMatrix.

The company presented data at the Cambridge Healthtech Institute's Molecular Medicine Tri-Conference in San Francisco last week that showed that its so-called Comprehensive Cancer Array can detect "dramatically different" miRNA expression patterns in the blood of patients with Stage 1 to Stage 4 cancer compared to those who were cancer-free.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PLOS this week: canine GWAS of skeletal syndromes, Chagas disease outcomes and genetic ancestry, and more.

A team describes its idea for a clinical trial data-sharing database, called Vivli, ScienceInsider reports.

One case illustrates how DNA evidence can incriminate an innocent person, Scientific American says.

A lack of stability in research funding drives researchers away from academia, researchers write at eLife.